Fig. 7. Virotherapy of the TME results in distinct TIL phenotypes.

a Wt B16.F10 tumors implanted in CD155-tg mice were treated with i.t. mock (PBS), mRIPO (10⁷ pfu), LPS (30 μg), or Poly(I:C) (30 μg) with anti-PD-L1 therapy delivered i.p. to all groups as shown [n = 9 LPS, n = 8 for all other groups]; p-value is from two-way ANOVA vs mock. b CD155-tg mice bearing wt B16 tumors were treated with mRIPO (3 × 10⁷ pfu), Poly(I:C) (30 μg), or LPS (30 μg) for analyses in (c–e). c Tumor homogenate cytokines represented as %max for each cytokine followed by subtraction of mean PBS values (n = 4 PBS, n = 5 others) were measured 1 day after treatment. d Tumor immune cell subtypes as %live singlets at days 1 (top; n = 3 PBS, n = 5 others) and 7 [bottom; pooled from 2 experiments: n = 7 PBS, n = 8 Poly(I:C), n = 9 others]; mean −/+ SEM is shown. e TAM (n = same as d, day 7) or T cell activation markers for three experiments [n = 9 PBS, n = 11 mRIPO/Poly(I:C), n = 12 LPS]. Extended associated analyses and gating are shown in Supplementary Fig. 10; (c–e) asterisks denote two-tailed Tukey’s post-hoc test p < 0.05 compared to (*) mock, (†) LPS, or (#) all groups.